Contract development and manufacturing organisation (CMDO) Matica Biotechnology has opened a new facility for the production of viral vectors and cell-based products used in cell and gene therapies, vaccines, oncolytic therapies and other genetic medicines.
Through the facility, Matica Bio is expanding its capacity as a CDMO and is responding to the industry’s need for faster delivery cells and viral vectors that are important components of some of the most promising novel therapies.
To keep pace with accelerated clinical development time frames, production complexities and demand, Matica Bio is working with two companies at the new facility. The company has partnered with Sartorius to develop and optimise advanced viral vector manufacturing technologies for large-scale vector production and also with Texas A&M University’s Center for Innovation in Advanced Development and Manufacturing for projects to speed up biotech R&D and commercial manufacturing.
“The key is faster delivery without sacrificing quality or safety,” said Matica Bio CEO Yun Jeong Song. “Our new facility is designed for rapid development, scale-up and production for clinical supply, but our experienced teams provide quality oversight and regulatory guidance necessary to ensure success. Solely committed to our clients’ commercialization goals, we have the expertise and an advanced, modular system that provides the flexibility to adjust resources required depending on client need and product requirements.”
“We’re aiming to improve multiple components across the cell and gene therapy production process, including ease of manufacturability, real-time data read-outs, reducing costs and solving anticipated challenges of large-scale cell culture and viral vector production,” said Matica Bio Chief Technology Officer Mike Stewart. “These collaborations are just the start of Matica Bio’s commitment for future expansion of research, expertise and successful product development.”